Hepatitis/MASH

Long-term infections with other pathogens have been suspected as the cause of mental impairment in patients with HIV. However, new research suggests that this might not be the case.

To curb an estimated 6% to 11% increase in Medicare Part D spending, 3 states have already placed limitations on which patients with chronic hepatitis C are candidates for treatment with novel antiviral agents.

The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus and hepatitis C virus infection by focusing on the most vulnerable, high-risk patient populations.

Protective strategy may keep organs safe and functioning optimally after the procedure.

Three-drug regimen will lead to new treatment protocols for transplant patients, study finds.

A study from Merck has demonstrated high response to grazoprevir/elbasvir with and without ribavirin across various hepatitis C virus populations, including difficult-to-cure patients.

A trio of studies from AbbVie provides good news for patients with hepatitis C virus, including those with comorbid HIV or cirrhosis.

Gilead Sciences Inc. has reported positive results from its phase 2 and phase 3 studies on ledipasvir 90 mg/sofosbuvir 400 mg in patients with chronic hepatitis C virus.

A study exploring Merck's experimental hepatitis C virus treatment has provided proof-of-concept for a 6- to 8-week course of triple therapy.

Sovriad found to have caused significant increase in blood bilirubin levels in deceased patients.

Hexavalent vaccine protects against diphtheria, tetanus, pertussis, polio, invasive disease caused by Haemophilus influenzae type b, and hepatitis B.

The FDA is reviewing a Biologics License Application for the first pediatric combination vaccine designed to help protect against 6 diseases.

SVR12 rates significantly higher in patients treated with daclatasvir/peginterferon alfa/ribavirin combination.

Provides use, cost forecast based on testing, future treatment rates.

Harvoni is comprised of sofosbuvir, a previously approved HCV drug marketed under the brand name Sovaldi, and a new drug called ledipasvir.

The drugmaker will no longer pursue FDA approval of its dual daclatasvir and asunaprevir treatment for patients with hepatitis C virus genotype 1b.

Researchers from Saint Louis University Medical Center will test the safety and efficacy of sofosbuvir and ribavirin in children with hepatitis C.

Investigators aim to reduce side effects of therapy with sofosbuvir in children with hepatitis C.

Among HIV-positive patients, concurrent use of medications is associated with nonadherence to antiretroviral therapy.

Much higher rate of patients in real world discontinuing high priced treatment than during clinical studies.

Results of a phase 3 trial demonstrate the effectiveness of simeprevir in combination with ribavirin and peginterferon as a treatment for patients coinfected with HIV and HCV.

Data indicates that a simeprevir-based therapy is efficacious in patients with HIV-1/HCV genotype 1 coinfection.

A recent study published in the journal Hepatology indicates that as many as 11% of baby boomers had a positive test result for presence of anti-HCV antibodies.

Study finds HIV suppression reduces hepatitis C viral replication over time.